PBGENE-HBV shows 1-log cccDNA reduction; DMD trial activates second site

PRECISION BIOSCIENCES INC

PBGENE-HBV in ELIMINATE-B study demonstrated 1-log (10-fold) reduction in cccDNA-derived transcripts from liver biopsy.
Company targets year-end 2026 for next program update on chronic hepatitis B.
FUNCTION-DMD trial for Duchenne muscular dystrophy activated second clinical site at Washington University in St. Louis.
Initial safety data from DMD trial targeted for year-end 2026.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.